设为首页|加入收藏|英文版

总体介绍

首页 > 广东省中医药科学院 > 总体介绍

恶性肿瘤辨证论治与精准治疗研究团队

2017/7/15 10:50:03字号:T|T

 

恶性肿瘤辨证论治与精准治疗研究团队以全国名老中医刘伟胜教授为学术顾问,张海波教授为学术带头人。团队与中国科学院北京基因组研究所、美国MD Anderson 癌症中心、美国UCLA大学、英国Cardiff大学合作,研究内容涵盖恶性肿瘤的中西医结合基础与临床研究,包括中医辨证标准化,分子病理学,液体活检,中医药临床研究,中药药理学,基因组学、代谢组学等多学科研究,致力于提高恶性肿瘤中西医结合治疗水平,并推进中医药国际化。

Malignant Tumor TCM Syndrome Differentiation and Precision Medicine Research Team is led by professor Haibo Zhang. Professor Weisheng Liu, the National Famous Doctor of TCM, gives academic advices for the researches. This team have cooperation with Beijing Institute of Genomics, Chinese Academy of Science, MD Anderson Cancer CenterUCLA, and Cardiff University. We focus on the basic and clinical researches about malignant tumor, aiming to improve the efficacy of comprehensive treatment combining TCM and western medicine and for malignant tumor, and to go forward for the TCM internationalization. Our researches cover standardization of TCM syndrome differentiation, molecular pathology, liquid biopsy, clinical trials about Chinese medicine, pharmacology of TCM, Genomics, and metabonomics studies and so on.

队主攻方向 Main direction

1.IIIB/IVNSCLC患者中医辨证分型与分子病理分型(NGS)、EGFR基因状态、EGFR-TKIs疗效及耐药之间的基础与临床研究。

Basic and Clinical Researches about the relationship between TCM syndrome types and molecular pathological types, EGFR status and efficacy of EGFR-TKIs in NSCLC patients.

基于中医的“同病异治”理论和西医的“精准医学”理念,以IIIB/IV期非小细胞肺癌患者为研究对象,通过分析患者不同的中医辨证分型与各自分子病理分型间的相关性,建立NSCLC患者宏观辨证分型与微观分子分型的网状模型,同时观察中医辨证分型、分子病理分型与疗效及预后的关系,从而为中医的辨证分型提供客观物质基础,为传统中医理论的现代化提供理论基础和依据,并建立中医辨证分型、分子病理分型分布数据库,为下一步指导中医治则、治法、用药及“精准医学”新药开发提供前期临床流行病学数据。通过细胞、动物实验及临床观察的证候演变规律,明确何种治法中药对EGFR-TKIs具有协同作用,为以后临床选用合适治则方药联合治疗NSCLC提供指导原则并为逆转EGFR-TKIs药物耐药提供理论基础。


According to TCM theory, we may treat patients with same disease using different therapies, which was similar to the concept of Precision Medicine. We enrolled stage IIIB/IV NSCLC patients, analyzed the relationship between the TCM syndrome types and molecular pathological types, in order to establish a network model. We also observed the efficacy and prognosis with different TCM syndrome types and molecular pathological types. According to this data, we may find out the material basis for TCM syndrome types, and provide epidemiological basis for further studies about TCM treatment principles, TCM herbs and Precision new drug researches for NSCLC patients. We also hold cellular and animal studies to prove our previous findings.


2.中医药联合化疗对EGFR野生型的IIIB/IV期非小细胞肺癌维持治疗研究。

Efficacy of TCM combining with maintenance therapy in stage IIIB/IV NSCLC patients harboring wild-type EGFR gene.

EGFR野生型的IIIB/IV期非小细胞肺癌为研究对象,探讨一线常规化疗后,中医药联合化疗的维持治疗作用。同时在治疗前对患者中医“寒”“热”“瘀”证型进行分层,明确中医证型与上述药物疗效及生存的关系,以期寻找到一种延缓甚至肺癌进展的新方法,部分解决目前肺癌治疗的瓶颈问题。

  We are enrolling Stage IIIB/IV NSCLC patients who harbor wild-type EGFR gene, and will observe the efficacy of TCM combining with maintenance therapy after first line chemotherapy. We also analyze the relationship between TCM syndrome types, including Yin-cold, Yang-heat and blood-stasis, and efficacy of maintenance TCM and chemotherapy. We are trying to find a new way to improve the efficacy for wild-type EGFR NSCLC patients   


3. 肠癌患者中医辨证分型与分子病理分型、肠道微生物菌群宏/泛基因组相关性的基础与临床研究

Basic and Clinical Researches about the relationship between TCM syndrome types and molecular pathological types and gut microbiome/microbiota in colorectal cancer patients

基于中医证候理论,探讨肠癌患者中医辨证分型与西医肠道微生物菌群的相关性,尤其是III期肠癌术后患者中药治疗后辨证分型的变化规律和肠道微生物菌群的变化规律,明确何种中药可以延缓肠癌术后复发,并从肠道微生物菌群宏/泛基因组角度探讨中药治疗肠癌的可能机制。

  We are analyzing the relationship between TCM syndrome types and gut microbiome/microbiota, especially the changes in TCM syndrome types and gut microbiome/microbiota after TCM treatments in patients with stage III colorectal cancer after resection. We are trying to find TCM treatments to delay recurrence for these patients, and to reveal the possible mechanism of the TCM efficacy, using gut microbiome/microbiota analysis methods.

 

团队主要成员 Members of the team

 

学术带头人 Academic leader

张海波  主任医师,教授,医学博士。广东省中医院肿瘤科科主任,博士研究生导师,香港浸会大学临床教研中心及美国MD.安德森肿瘤中心访问教授中国中医科学院中青年名中医;广东省千百十工程人才培养对象;广东省卫生系统“青年岗位能手”。美国肿瘤临床协会(ASCO)委员;中国肿瘤临床协会(CSCO)青年委员;中华中医药学会(CACM)肿瘤青年专业委员会副主任委员;中国老年肿瘤康复专业委员会(CGOS)常委;广东省医院协会分子靶向治疗专业委员会副主任委员;广东省中医肿瘤康复与治疗专业委员会副主任委员;广东省中医肿瘤专业委员会常委,广东省抗癌协会(GDACA)靶向与个体化治疗专业委员会常委,肺癌、大肠癌专业委员。国家自然基金项目评审专家;ESMO官方杂志Annals of oncology中文版、中医杂志、重庆医学、疑难病杂志等知名杂志编委近年主编及参编肿瘤专著4部,在国内外期刊发表论文40余篇。目前主持国家自然基金科研项目1项;广州市科创委健康医疗协同创新重大专项1;国际合作项目——加拿大TerryFox癌症基金2项;卫生部、民政部科研课题各1项;广东省科技厅科研课题2项;CSCO同辉基金1项;吴阶平基金会肿瘤专项基金课题1项;参与国家“十五” “十一五”科技攻关、卫生部、上海市、广东省以及广州中医药大学等各级科研课题10余项。获广州中医药大学科技进步二等奖2项。主要从事肺癌、胃肠癌等恶性肿瘤的中西医临床与临床基础研究。

Professor Haibo Zhang, chief physician, M.D.&Ph.D, MD student supervisor, is the chief of Oncology Department of Guangdong Provincial Hospital of Chinese Medicine. He specializes in helping cancer patients by combining TCM and Western approaches, especially for those with lung cancer and colorectal cancer. He focuses on the basic and clinical studies about combination of TCM and Western medicine in cancer. He worked as a visiting scholar in the Hong Kong Yan-chai Hospital and the Hong Kong Baptist University Clinical Research Center in 2007 and 2008, and is now working as a visiting scholar in MD Anderson cancer center. He received the award as Youth Famous TCM Doctor from China Academy of Chinese medical Science, the training award from Guangdong Province’s “Thousand-Hundred-Ten” Program, the award as Youth Skilled Expert from Guangdong Provincial Health System. Currently, he is a member of  American Society of Clinical Oncology (ASCO), a youth member of Chinese Society of Clinical Oncology (CSCO), a vice chairman of Youth Oncologists of China Association of Chinese Medicine (CACM), a standing member of Chinese Geriatric Oncology Society (CGOS), a vice chairman of the Molecular Targeted Therapy Committee of Guangdong Provincial Hospital Association, a vice chairman of the Guangdong Provincial TCM Tumor Rehabilitation and Treatment Committeea standing member of Guangdong TCM Oncology Committee, a standing member of Targeted and Personal Therapy Committee and an expert member of Lung cancer and Colorectal Cancer Committee of Guangdong Provincial Anti-cancer Association (GDACA). He is also a reviewer expert of Natural Science Foundation of China (NSFC), an editorial member of the Famous Journals, such as Chinese Edition of Annals of Oncology, Journal of Traditional Chinese Medicine, Chongqing Medical Journal, Journal of Difficult Diseases, and so on. He co-edited and was a book chapter contributor for 4 college text books. He published more than 40 papers. Currently, he is in charge of many research projects, including those funded by Natural Science Foundation of China (NSFC), Major Projects of Collaborative Innovation in Health Care of Science and Technology Program of Guangzhou, Canadian Terry Fox Foundation, Chinese Ministry of Civil Affairs Grant, Chinese Ministry of Health Grant, Science and Technology Department of Guangdong Province Foundation, CSCO Foundation, Wu Jieping Foundation, and so on. He also worked as principle a co-investigator in many other research projects, including those funded by the National “10th Five-year" and 11th Five-year Technology Support Program. He has won the second prize of Science and Technology Advance twice from Guangzhou University of TCM.


学术骨干Academic backbone

朱燕娟  医学硕士,主治医师,肿瘤整合医学学会(SIO)委员。主持吴阶平医学基金课题1项,参与恶性肿瘤相关国家级、省部级、厅局级课题6项,参编肿瘤专著1部,发表SCI论文多篇。

Yan-juan Zhu, Master of Medicine, Chief physician, is a member of Society of Integrative Oncology (SIO). She is now chairing 1 research project Funded by Wu Jieping Foundation, and participating in 6 projects Funded by national, provincial and city level Fundation. She was a book chapter contributor for 1 college text book. She has also published a number of academic articles indexed by SCI.


















首页|网站地图|法律申明|友情链接|招聘信息|供应商管理|名老中医学术交流|中医健康管理|中医医案管理 |知识管理|在线考试